Innovative treatment of age-related hearing loss using MSCs and EVs with Apelin.

Shengqun Xu, Dongliang Liu, Fang Zhang, Yuan Tian

Ear, Nose, Throat, Head and Neck Surgery Comprehensive Ward, Shengjing Hospital of China Medical University, Shenyang, 110020, China.Ear, Nose, Throat, Head and Neck Surgery Comprehensive Ward, Shengjing Hospital of China Medical University, Shenyang, 110020, China. · pubmed

Paper

Abstract

Utilizing single-cell transcriptome sequencing (scRNA-seq) technology, this study explores the viability of employing mesenchymal stem cells (MSCs) as a therapeutic approach for age-related hearing loss (ARHL). The research demonstrates MSCs' ability to differentiate into inner ear cell subpopulations, particularly hair cells, delivering Apelin via extracellular vesicles (EVs) to promote M2 macrophage polarization. In vitro experiments show reduced inflammation and preservation of hair cell health. In elderly mice, MSCs transplantation leads to hair cell regeneration, restoring auditory function. These findings highlight the regenerative capabilities of MSCs and EV-mediated therapeutic approaches for ARHL.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that mesenchymal stem cells (MSCs) can regenerate hair cells and restore auditory function in age-related hearing loss through the delivery of Apelin via extracellular vesicles (EVs). This research addresses a specific age-related condition and explores a potential regenerative therapy, which aligns with the goals of longevity research.

Author of this paper? Send a correction.